These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 10607431

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Effect of mycophenolate mofetil on severity of nephritis and nitric oxide production in lupus-prone MRL/lpr mice.
    Lui SL, Tsang R, Wong D, Chan KW, Chan TM, Fung PC, Lai KN.
    Lupus; 2002; 11(7):411-8. PubMed ID: 12195781
    [Abstract] [Full Text] [Related]

  • 5. 15-Deoxyspergualin and cyclophosphamide, but not mycophenolate mofetil, prolong survival and attenuate renal disease in a murine model of ANCA-associated crescentic nephritis.
    Birck R, Newman M, Braun C, Neumann I, Nemoto K, Yard B, Waldherr R, van der Woude FJ.
    Nephrol Dial Transplant; 2006 Jan; 21(1):58-63. PubMed ID: 16141461
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Anti-Ccl2 Spiegelmer permits 75% dose reduction of cyclophosphamide to control diffuse proliferative lupus nephritis and pneumonitis in MRL-Fas(lpr) mice.
    Kulkarni O, Eulberg D, Selve N, Zöllner S, Allam R, Pawar RD, Pfeiffer S, Segerer S, Klussmann S, Anders HJ.
    J Pharmacol Exp Ther; 2009 Feb; 328(2):371-7. PubMed ID: 18997060
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Immunosuppression With Mycophenolate Mofetil Attenuates Hypertension in an Experimental Model of Autoimmune Disease.
    Taylor EB, Ryan MJ.
    J Am Heart Assoc; 2017 Feb 27; 6(3):. PubMed ID: 28242635
    [Abstract] [Full Text] [Related]

  • 10. Changes in immune cell frequencies after cyclophosphamide or mycophenolate mofetil treatments in patients with systemic lupus erythematosus.
    Zhao L, Jiang Z, Jiang Y, Ma N, Wang K, Zhang Y.
    Clin Rheumatol; 2012 Jun 27; 31(6):951-9. PubMed ID: 22349930
    [Abstract] [Full Text] [Related]

  • 11. Differential effects of cyclophosphamide and mycophenolate mofetil on cellular and serological parameters in patients with systemic lupus erythematosus.
    Fassbinder T, Saunders U, Mickholz E, Jung E, Becker H, Schlüter B, Jacobi AM.
    Arthritis Res Ther; 2015 Apr 03; 17(1):92. PubMed ID: 25890338
    [Abstract] [Full Text] [Related]

  • 12. 4SC-101, a novel small molecule dihydroorotate dehydrogenase inhibitor, suppresses systemic lupus erythematosus in MRL-(Fas)lpr mice.
    Kulkarni OP, Sayyed SG, Kantner C, Ryu M, Schnurr M, Sárdy M, Leban J, Jankowsky R, Ammendola A, Doblhofer R, Anders HJ.
    Am J Pathol; 2010 Jun 03; 176(6):2840-7. PubMed ID: 20413687
    [Abstract] [Full Text] [Related]

  • 13. Mycophenolate mofetil reduces renal cortical inducible nitric oxide synthase mRNA expression and diminishes glomerulosclerosis in MRL/lpr mice.
    Yu CC, Yang CW, Wu MS, Ko YC, Huang CT, Hong JJ, Huang CC.
    J Lab Clin Med; 2001 Jul 03; 138(1):69-77. PubMed ID: 11433230
    [Abstract] [Full Text] [Related]

  • 14. Vasculitis in the Palmerston North mouse model of lupus: phenotype and cytokine production profile of infiltrating cells.
    Luzina IG, Knitzer RH, Atamas SP, Gause WC, Papadimitriou JC, Sztein MB, Storrer CE, Handwerger BS.
    Arthritis Rheum; 1999 Mar 03; 42(3):561-8. PubMed ID: 10088780
    [Abstract] [Full Text] [Related]

  • 15. Cyclophosphamide treatment for hypertension and renal injury in an experimental model of systemic lupus erythematosus.
    Wolf VL, Taylor EB, Ryan MJ.
    Physiol Rep; 2019 May 03; 7(10):e14059. PubMed ID: 31124322
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Mycophenolate mofetil but not atorvastatin attenuates atherosclerosis in lupus-prone LDLr(-/-) mice.
    van Leuven SI, Mendez-Fernandez YV, Wilhelm AJ, Wade NS, Gabriel CL, Kastelein JJ, Stroes ES, Tak PP, Major AS.
    Ann Rheum Dis; 2012 Mar 03; 71(3):408-14. PubMed ID: 21953346
    [Abstract] [Full Text] [Related]

  • 19. A benzenediamine derivative fc-99 attenuates lupus-like syndrome in MRL/lpr mice related to suppression of pDC activation.
    Ji J, Fan H, Li F, Li X, Dong G, Gong W, Song Y, Liu F, Hua C, Tan R, Dou H, Hou Y.
    Immunol Lett; 2015 Dec 03; 168(2):355-65. PubMed ID: 26545567
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.